# DESCRIPTION

## FIELD OF THE INVENTION

- relate to phthalimide derivatives of non-steroidal anti-inflammatory and/or TNF-α modulators

## BASIS OF THE INVENTION

- introduce inflammation
- describe acute and chronic inflammation
- discuss the use of medicinal substances to treat pain and fever
- introduce non-steroidal anti-inflammatory drugs (NSAIDs)
- describe the mechanism of action of NSAIDs
- discuss the discovery of COX-1 and COX-2
- describe the physiological role of COX-2
- discuss the development of COX-2 selective NSAIDs
- describe the limitations of COX-2 selective NSAIDs
- discuss the neuroprotective action of NSAIDs
- describe the relationship between NSAIDs and Alzheimer's disease
- discuss the adverse effects of NSAIDs
- describe the gastrointestinal toxicity of NSAIDs
- discuss the role of TNF-α in inflammation
- describe the pro-inflammatory effects of TNF-α
- discuss the inhibition of TNF-α
- describe the therapeutic effects of anti-TNF-α antibodies
- discuss the analgesic effect of thalidomide
- describe the anti-inflammatory and immunomodulatory properties of thalidomide
- discuss the development of thalidomide analogues
- describe the role of TNF-α in chronic inflammatory diseases
- discuss the strategy of inhibiting TNF-α
- describe the molecular modification of drugs
- discuss the use of molecular latentiation and hybridization
- describe the preparation of hybrid compounds of NSAIDs with furoxanic subunit
- discuss the anti-inflammatory, gastrosparing, and anti-platelet properties of new NO-donor esters of aspirin
- describe the need for new compounds with anti-inflammatory and analgesic activity
- discuss the molecular hybridization strategy between phthalmidic subunit of thalidomide and NSAIDs
- describe the therapeutic advantages of new compounds
- discuss the potential of new compounds in treating chronic inflammatory diseases
- describe the limitations of current treatments for chronic inflammatory diseases
- discuss the need for alternative treatments
- describe the importance of minimizing side and adverse effects
- discuss the potential of new compounds in improving patient's life quality
- describe the potential of new compounds in treating diseases such as Alzheimer's and Parkinson's

## SUMMARY OF THE INVENTION

- introduce the invention
- describe the new NSAID's phthalimide derivatives
- discuss the therapeutic advantages of new compounds

## Where:

- define NSAID
- define W
- define X
- list substituents for W
- list options for X
- describe compounds of the invention
- introduce pharmaceutical compositions
- describe method to obtain phthalimide derivatives
- outline alternative processes

## DETAILED DESCRIPTION OF THE INVENTION

- introduce process for obtaining phthalimide derivatives
- describe innovative features of the invention
- illustrate activity of compound obtained from Example 1.3
- present preferred NSAIDs phthalimide derivatives
- illustrate synthetic route of preparation
- describe convergent syntheses
- outline synthetic route in Scheme 2
- describe alternative synthetic route in Scheme 3
- discuss administration of compounds
- describe pharmaceutical compositions
- outline preparation of pharmaceutical compositions
- list examples of diluents
- list examples of other pharmaceutical composition components

## EXAMPLES

### Example 1

- prepare compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)-2
- synthesize methyl salicylate
- synthesize 2-hydroxybenzohydrazide intermediary
- synthesize compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)-

### Example 2

- prepare compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)-2
- synthesize methyl 2-(4-isobutylphenyl) propanoate
- synthesize 2-(4-isobutylphenyl) propanohydrazide
- synthesize compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)
- describe NMR H1 spectrum
- describe NMR C13 spectrum
- describe IR spectrum

### Example 3

- prepare compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)-2
- synthesize methyl 2-(6-methoxy-2-naftyl) propanoate
- synthesize 2-(6-methoxy-2-naftyl) propanohydrazide
- synthesize compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)
- describe NMR H1 spectrum
- describe NMR C13 spectrum
- describe IR spectrum
- describe physical properties

### Example 4

- prepare compound 2-(3-benzoylphenyl)-N-(1,3-dioxy-1,3-dihydro-2
- synthesize methyl 2-(3-benzoylphenyl) propanoate
- synthesize 2-(3-benzoylphenyl) propanohydrazide
- synthesize compound 2-(3-benzoylphenyl)-N-(1,3-dioxy-1,3-dihydro-
- describe NMR H1 spectrum
- describe IR spectrum

### Example 5

- synthesize compound 2
- synthesize intermediary methyl ester
- synthesize intermediary hydrazide
- synthesize final product
- provide IR spectrum
- provide NMR spectra

### Example 6

- synthesize compound 2
- synthesize intermediary methyl ester
- synthesize intermediary hydrazide
- synthesize final product
- provide IR spectrum
- provide NMR spectra

### Example 7

- introduce hybrid derivatives
- synthesize compound 7.1
- provide IR spectrum of 7.1
- provide NMR spectra of 7.1
- synthesize compound 7.2
- provide IR spectrum of 7.2
- provide NMR spectra of 7.2

## Tests of the Rat Paw Edema Incuded by Carrageenin Utilizing The Compounds of the Invention Obtained in Examples 1.3, 2.3, 3.3, 5.3 and 6.3

- evaluate anti-inflammatory activity

## Example 8

### Test of Paw Edema Induced by Carrageenin with Pre-Treatment with the Compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)-2-hydroxybenzamide (derivative from salicylic acid)

- evaluate anti-inflammatory activity

## Example 9

### Test of Paw Edema Induced by Carrageenin with pre-treatment with the compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)-2-(4-isobutylphenl) propanamide

- evaluate anti-inflammatory activity

### Example 10

- evaluate anti-inflammatory activity
- discuss TNF-α inhibition

### Example 11

- evaluate anti-inflammatory activity
- compare with diclofenac

### Example 12

- evaluate anti-inflammatory activity

### Example 13

- introduce gastric damage test
- describe test methodology
- evaluate compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)-2
- compare with salicylic acid
- evaluate compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)-2
- compare with ibuprofen
- evaluate compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)-2
- compare with naproxen
- evaluate compound 2-{2-[(2,6-dichlorophenyl) amine]phenyl}-N-(1,3-d
- compare with diclofenac
- evaluate compound 2-{2-[(2-chloro-6-fluorophenyl) amine]-5-methyl
- compare with lumiracoxib
- discuss gastric ulceration
- compare with NSAIDs
- conclude safety of compounds

### Example 14

- introduce abdominal contortion test
- describe test methodology
- evaluate compounds at 1 μmol/kg
- evaluate compounds at 100 μmol/kg
- discuss peripheral analgesic activity
- conclude analgesic activity

### Methodologies Used for the Pharmacological Tests

- describe rat paws edema test
- describe gastric lesion test
- describe abdominal contortion test
- discuss carrageenan injection
- discuss pre-treatment with compounds
- discuss measurement of paw thickness
- discuss gastric ulcerogenesis
- discuss statistical analysis
- conclude methodologies

